-- 醫藥巨頭海泰製藥（HKG:2511）週一在香港交易所發佈公告稱，已同意向其首席執行官劉麗萍提供至多1500萬港元的貸款。 週二午後交易時段，該公司股價下跌1%。 根據該貸款安排，貸款將於提取後一年償還，年利率為3.50%。
Related Articles
Asia
Rate Increases Have Limited Impact on Japanese Borrowers' Credit Quality, S&P Says
Increasing interest rates will not have a significant effect on Japanese borrowers' creditworthiness, although repayment burdens could intensify if the rise in rates continues, S&P Global Ratings said in a Tuesday release.The rating agency expects limited impact on repayment capacity from higher interest rates as residential mortgage-backed securities (RMBS) are usually backed by fixed-rate housing loans, S&P said.However, rate increases could heighten total borrowing, especially under increased real estate prices, S&P said.The spike in housing prices is likely due to increased employment costs and a sustained rise in imported material prices, the rating agency said.Still, S&P expects that even under the most severe stress scenario, tranches to be downgraded would only have a 17% share of all rated RMBS transactions and still lead to ratings of A+ or higher.
$^N225
Asia
Mitsubishi Electric's Fiscal-Year Profit Jumps 26%
Mitsubishi Electric's (TYO:6503) profit attributable to owners of the parent jumped 26% to 407.7 billion yen for the fiscal year ended March 31 from 324 billion yen a year earlier.The electronics company's earnings per share increased to 198.31 yen from 155.70 yen a year ago, according to a Tokyo bourse filing on Tuesday.Revenue climbed 7% to 5.895 trillion yen from 5.522 trillion yen in the prior year.It declared a final dividend of 30 yen per share for the fiscal 2026, payable from June 2.For the fiscal year ending March 31, 2027, the company expects attributable profit of 475 billion yen and net sales of 6.2 trillion yen.Mitsubishi Electric plans to pay interim and year-end dividends of 25 yen and 30 yen per share, respectively, for the current fiscal year (total 55 yen), which is higher than the amount paid in the year-ago period.
$TYO:6503
US Markets
Novartis Reports First-quarter Sales Dip Amid Growing US Generic Competition
Novartis (NOVN.SW) on Tuesday reported a decline in first-quarter sales as an expected rise in generic penetration in the US outweighed the momentum of priority brands.Shares in the Swiss drugmaker was down 4% by midday trading.For the three months ended March 31, net sales were down 5% at constant currency to $13.11 billion. Volume added 13 percentage points to growth, but this was more than offset by a hit of 14 percentage points due to generic competition.Key therapies that continued to perform include leukemia treatment Scemblix, which surged 79% at constant currency to $433 million, and breast cancer drug Kisqali, which rose 55% to $1.52 billion. Conversely, revenue from heart failure drug Entresto dropped 46% to $1.31 billion.Against this backdrop, Novartis reiterated its 2026 financial targets, projecting low single-digit growth for net sales alongside a low single-digit decline in core operating income. Should late April exchange rates hold steady through year-end, currency tailwinds are projected to add 2 percentage points to net sales and 1 percentage point to core operating income, the company noted."With the momentum we are seeing across the business, we remain on track to deliver our [full-year] guidance and look forward to multiple readouts in the second half that could raise our mid- to long-term growth outlook," Novartis Chief Executive Officer Vas Narasimhan said.Novartis' net income reached $3.16 billion in the first quarter, down from $3.61 billion in the same period a year ago. EPS dropped to $1.65 from $1.83
$NOVN.SW